Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof
Methods and composition related to the engineering of a novel protein with methionine-γ-lyase enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-γ-lyase (CGL) comprising one or more amino acid substitutions and capable of degrading methionine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with methionine depletion using the disclosed proteins or nucleic acids.
1. A polypeptide comprising a variant of a primate cystathionine gamma-lyase, wherein the variant crysathionine gamma lyase has methionine gamma-lyase activity, a sequence at least 95% identical to SEQ ID NO:1, and comprises amino acid substitutions at amino acid positions corresponding to positions 59, 119 and/or 339 of SEQ ID NO: 1, the native human cystathionine gamma lyase, said substitutions being i) E59V or E59N, ii) R119L and iii) E339V.
2. The polypeptide of claim 1 , wherein the cystathionine gamma lyase is human cystathionine gamma-lyase comprising SEQ ID NO:1 having the i) E59V or E59N, ii) R119L and/or iii) E339V substitutions.
3. The polypeptide of claim 1 , wherein the variant primate cystathionine gamma-lyase has at least 98% sequence identity to the sequence of SEQ ID NO:1 having the i) E59V or E59N, ii) R119L and/or iii) E339V substitutions.
4. The polypeptide of claim 1 , further comprising a heterologous peptide segment.
5. The polypeptide of claim 4 , wherein the heterologous peptide segment is an XTEN peptide.
6. The polypeptide of claim 1 , wherein the polypeptide is coupled to polyethylene glycol (PEG).
7. The polypeptide of claim 6 , wherein the polypeptide is coupled to PEG via one or more Lys or Cys residues.
8. The polypeptide of claim 1 , comprising amino acid substitutions at each amino acid of positions 59, 119 and 339 of the native cystathionine gamma lyase, said substitutions being i) E59V or E59N, ii) R119L and iii) E339V.
9. The polypeptide of claim 8 , comprising amino acid substitutions at each amino acid of positions 59, 119 and 339 of the native cystathionine gamma lyase, said substitutions being i) E59V, ii) R119L and iii) E339V.
10. The polypeptide of claim 8 , comprising amino acid substitutions at each amino acid of positions 59, 119 and 339 of the native cystathionine gamma lyase, said substitutions being i) E59N, ii) R119L and iii) E339V.
11. A pharmaceutical formulation comprising the polypeptide of claim 1 in a pharmaceutically acceptable carrier.
12. A method of treating a tumor cell or subject having a tumor cell comprising administering to the tumor cell or the subject the formulation of claim 11 .
13. The method of claim 12 , wherein the subject is maintained on a methionine restricted diet.
14. The method of claim 12 , wherein the subject is maintained on a normal diet.
15. The method of claim 12 , wherein the subject is a human patient.
16. The method of claim 12 , wherein the tumor cell is a cell of breast cancer, prostate cancer, neuroblastoma or pancreatic carcinoma.
17. The method of claim 12 , wherein the formulation is administered intravenously, intradermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostaticaly, intrapleurally, intratracheally, intraocularly, intranasally, intravitreally, intravaginally, intrarectally, intramuscularly, subcutaneously, subconjunctival, intravesicularlly, mucosally, intrapericardially, intraumbilically, orally, by inhalation, by injection, by infusion, by continuous infusion, by localized perfusion bathing target cells directly, via a catheter, or via a lavage.
18. The method of claim 12 , wherein the formulation is administered to a nutrient medium of the tumor cell.
19. The method of claim 18 , wherein the nutrient medium is blood, lymphatic fluid, or spinal fluid.